CDEK
← All drugs Report issue

pf-00610355

Small moleculeexperimental

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2007 (NCT00468975)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1
Mol. weight
617.77 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • n-((4'-hydroxybiphenyl-3-yl)methyl)-2-(3-(2-((-2-hydroxy-2-(4-hydroxy-3-((methylsulfonyl)amino)phenyl)ethyl)amino)-2-methylpropyl)phenyl)acetamide
  • pf-00610355
  • pf-00610355
  • pf-00610355
  • pf-00610355
  • pf610355
  • pf 610355
  • pf-610355
  • pf-610355
  • pf-610355

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01107054Phase 1Jun 1, 2010Pfizer
NCT00808288Phase 2Mar 1, 2010Pfizer
NCT00830427Phase 2Jul 1, 2009Pfizer
NCT00783406Phase 2Oct 1, 2008Pfizer
NCT00468975Phase 2May 1, 2007Pfizer
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit5522007
1 organizations
Page 1 / 1